Patents by Inventor Sher Bahadur Karki

Sher Bahadur Karki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Optimized Fc Variants and Methods for their Generation
    Publication number: 20130058919
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Application
    Filed: February 27, 2012
    Publication date: March 7, 2013
    Applicant: XENCOR, INC.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen Kohl Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Fc variants
    Patent number: 8388955
    Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: March 5, 2013
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John R. Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Optimized Fc variants and methods for their generation
    Patent number: 8383109
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: January 9, 2012
    Date of Patent: February 26, 2013
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Fc variants with altered binding to FcRn
    Patent number: 8367805
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: February 5, 2013
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Antibody variants with enhanced complement activity
    Patent number: 8362210
    Abstract: The present invention relates to novel Fc variants that comprise at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc receptor or ligand (e.g., Fc gamma R, C1q). Additionally, the Fc variants have altered complement dependent cytotoxicity (CDC) activity and/or antibody-dependent cell-mediated cytotoxicity (ADCC). The invention further provides methods and protocols for the application of said Fc variants, particularly for therapeutic purposes.
    Type: Grant
    Filed: January 19, 2011
    Date of Patent: January 29, 2013
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Sher Bahadur Karki, Gregory L. Moore
  • FC variants with altered binding to FCRN
    Patent number: 8338574
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: December 25, 2012
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20120321620
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: August 24, 2012
    Publication date: December 20, 2012
    Applicant: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Fc variants with altered binding to FcRn
    Patent number: 8324351
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: December 4, 2012
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Fc variants with altered binding to FcRn
    Patent number: 8318907
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: November 27, 2012
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION
    Publication number: 20120230980
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Application
    Filed: January 9, 2012
    Publication date: September 13, 2012
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Rudolph Desjarlais, Stephen Kohl Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • NOVEL IMMUNOGLOBULIN INSERTIONS, DELETIONS, AND SUBSTITUTIONS
    Publication number: 20120225058
    Abstract: An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more Fc?Rs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.
    Type: Application
    Filed: December 23, 2011
    Publication date: September 6, 2012
    Applicant: Xencor, Inc.
    Inventors: Gregory A. Lazar, Bassil I. Dahiyat, Wei Dang, Sher Bahadur Karki, Omid Vafa
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20120156207
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: November 10, 2011
    Publication date: June 21, 2012
    Applicant: Xencor, Inc.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20120156220
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: November 21, 2011
    Publication date: June 21, 2012
    Applicant: Xencor, Inc.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20120148578
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: November 21, 2011
    Publication date: June 14, 2012
    Applicant: XENCOR, INC.
    Inventors: SEUNG YUP CHU, JOHN R. DESJARLAIS, SHER BAHADUR KARKI, GREGORY ALAN LAZAR, GREGORY L. MOORE, IGOR VOSTIAR
  • Optimized FC variants
    Patent number: 8188231
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: May 5, 2005
    Date of Patent: May 29, 2012
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John R. Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Fc VARIANTS WITH ALTERED BINDING TO FcRn
    Publication number: 20120088905
    Abstract: The present application relates to a variant Fc region comprising the double mutation 428L/434S that increases serum half-life and the numbering is according to the EU index.
    Type: Application
    Filed: December 15, 2011
    Publication date: April 12, 2012
    Applicant: XENCOR, INC.
    Inventors: AARON KEITH CHAMBERLAIN, BASSIL I. DAHIYAT, JOHN R. DESJARLAIS, SHER BAHADUR KARKI, GREGORY ALAN LAZAR
  • OPTIMIZED ANTIBODIES THAT TARGET CD19
    Publication number: 20120082664
    Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Application
    Filed: August 30, 2011
    Publication date: April 5, 2012
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik WeiKing Pong, John O. Richards, Eugene Alexander Zhukovsky
  • Optimized Fc variants and methods for their generation
    Patent number: 8124731
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: February 28, 2012
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Immunoglobulin insertions, deletions and substitutions
    Patent number: 8101720
    Abstract: An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more Fc?Rs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.
    Type: Grant
    Filed: January 25, 2008
    Date of Patent: January 24, 2012
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Bassil I. Dahiyat, Wei Dang, Sher Bahadur Karki, Omid Vafa
  • Optimized Anti-CD30 Antibodies
    Publication number: 20120014943
    Abstract: An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.
    Type: Application
    Filed: June 17, 2011
    Publication date: January 19, 2012
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, John R. Desjarlais, Philip W. Hammond, David F. Carmichael, Bao-Iu Chen, Seung Y. Chu, Sher Bahadur Karki, Lori Kunkel